Catalent Widens OptiForm Solution Suite
Catalent Pharma Solutions has announced the broadening of the scope of its OptiForm Solution Suite, an integrated offering designed to help solve bioavailability challenges for early-stage molecules from late-stage discovery to Phase I clinical trials.
The OptiForm Solution Suite service will now include more candidate-screening tools, absorption, distribution, metabolism and excretion considerations and in silico drug metabolism and pharmacokinetic modeling, additional bioavailability-enhancing tools, materials for cGLP intravenous and oral toxicological studies, and cGMP materials for first-in-human studies, according to Catalent.
The new OptiForm Solution Suite integrates tools and services sequentially to deliver relevant data and an optimized development program to support a molecule’s progress toward the clinic.
Source: Catalent Pharma Solutions